Last updated: July 17, 2026

Application No. 18/140,344

Suppression of Microglial Activation with Innate Lymphoid Cells

Non-Final OA

Filed

Apr 27, 2023

Priority

Jul 16, 2018 — provisional 62/698,545 +1 more

Examiner

SAOUD, CHRISTINE J

Art Unit

1646

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Janssen Pharmaceutica N.V.

OA Round

1 (Non-Final)

This examiner grants 58% of cases after interview

— +37.9% interview lift. A telephonic interview to clarify the technical implementation could significantly improve the outcome.

Based on 758 resolved cases, 2023–2026

Examiner Intelligence

SAOUD, CHRISTINE J View full profile →

Grants 58% of resolved cases

Career Allowance Rate

440 granted / 758 resolved

-2.0% vs TC avg

Strong +38% interview lift

Without

With

+37.9%

Interview Lift

resolved cases with interview

Typical timeline

2y 10m

Avg Prosecution

34 currently pending

Career history

802

Total Applications

across all art units

Statute-Specific Performance

§101

4.6%

-35.4% vs TC avg

§103

27.8%

-12.2% vs TC avg

§102

10.3%

-29.7% vs TC avg

§112

26.7%

-13.3% vs TC avg

Black line = Tech Center average estimate • Based on career data from 758 resolved cases

Prosecution Timeline

Apr 27, 2023

Application Filed

May 20, 2026

Non-Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

17/936,073

Patent 12668624

ANTIBODY THAT BINDS TO VEGF AND PDGF-B AND METHODS OF USE

3y 9m to grant Granted Jun 30, 2026

17/640,083

Patent 12655204

ANTI-VEGF SINGLE-DOMAIN ANTIBODY AND USE THEREOF

4y 3m to grant Granted Jun 16, 2026

17/769,826

Patent 12656349

MEASUREMENT OF BEVACIZUMAB-INSENSITIVE VASCULAR ENDOTHELIAL GROWTH FACTOR-A

4y 2m to grant Granted Jun 16, 2026

18/166,996

Patent 12624098

TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND DIABETIC MACULAR EDEMA BY ADMINISTRATION OF A BISPECIFIC ANTIBODY TO VEGF AND ANG-2

3y 3m to grant Granted May 12, 2026

18/480,071

Patent 12624110

ANTIBODY TO INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF1R) AND RELATED COMPOSITIONS AND USES

2y 7m to grant Granted May 12, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

58%

Grant Probability

96%

With Interview (+37.9%)

2y 10m (~0m remaining)

Median Time to Grant

Low

PTA Risk

Based on 758 resolved cases by this examiner. Grant probability derived from career allowance rate.